Founded in 2021, ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level within a few hours, enabling the identification of TCR or antibody targets to develop more precise and effective immunotherapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/13/23 | $13,000,000 | Seed |
AV8 Ventures DCVC  Foundation Capital | undisclosed |
